Medarex to Present at the RBC Capital Markets Healthcare Conference
PRINCETON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at the RBC
Capital Markets Healthcare Conference at 3:30 p.m. Eastern Time on Wednesday,
December 10, 2008. The event will be webcast live and will be available in the
Investor Relations section of the Medarex website at www.medarex.com. An
archived edition of the presentation will be available following the event.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize a
broad range of fully human antibody product candidates for itself and its
partners. Over forty of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with the most advanced product candidates currently in Phase
3 clinical trials or the subject of regulatory applications for marketing
authorization. Medarex is committed to building value by developing a diverse
pipeline of antibody products to address the world's unmet healthcare needs.
For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.
